Sugi Predict

Sugi Predict / Compounds / SCHEMBL2019002

SCHEMBL2019002

SCHEMBL2019002

O=Cc1ccc(-c2cccc(Cl)c2)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRF1 P14222 2/20 0.56
▸ CYP2E1 P05181 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2A6 P11509 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ CYP2B6 P20813 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ APP P05067 1/20 0.49
▸ CNR1 P21554 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ DPP4 P27487 1/20 0.45
▸ IKBKB O14920 1/20 0.43
▸ HSD17B1 P14061 2/20 0.43
▸ HSD17B2 P37059 2/20 0.43
▸ PTPN1 P18031 1/20 0.41
▸ ESR1 P03372 2/20 0.41
▸ ESRRG P62508 2/20 0.41
▸ PGR P06401 2/20 0.41
▸ CYP1A1 P04798 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1133819 0.82 APP (0.54) PRF1CYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL30910015 0.81 PRF1 (0.45) PRF1CNR1IKBKBHSD17B1HSD17B2
SCHEMBL29215138 0.81 PRF1 (0.45) PRF1CNR1IKBKBHSD17B1HSD17B2
SCHEMBL70783 0.81 APP (0.67) PRF1CYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL9199395 0.79 CYP2E1 (0.54) PRF1CYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL5760473 0.79 CYP2E1 (0.54) PRF1CYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL2016059 0.79 HSD17B1 (0.56) PRF1CYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL7010956 0.79 CYP2A6 (0.54) PRF1CYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL18001816 0.79 APP (0.59) PRF1CYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL4636815 0.79 PRF1 (0.49) PRF1CYP2C9CNR1IKBKBHSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117430570-A Rhodamine acetic acid compound, and pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-01-23 — — CN disclosed
EP-3615514-B1 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS INC (US) 2023-11-22 — — EP disclosed
CN-110914242-B Propionic acid derivatives and methods of use thereof 阿维亚拉药品有限公司 2023-07-25 — — CN disclosed
EP-3226858-B1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS PROCOMCURE BIOTECH GMBH (AT) 2021-02-03 — — EP disclosed
US-10875875-B2 Propionic acid derivatives and methods of use thereof AVIARA PHARMACEUTICALS, INC. (US) 2020-12-29 — — US disclosed
CN-110914242-A Propionic acid derivatives and methods of use thereof 阿维亚拉药品有限公司 2020-03-24 — — CN disclosed
EP-3615514-A2 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF Aviara Pharmaceuticals, Inc. (US) 2020-03-04 — — EP disclosed
US-10456379-B2 Imidazole-based antimicrobial agents PROCOMCURE BIOTECH GMBH (AT) 2019-10-29 — — US disclosed
US-10322110-B2 Imidazole-based antimicrobial agents PROCOMCURE BIOTECH GMBH (AT) 2019-06-18 — — US disclosed
US-10314820-B2 Imidazole-based heterocyclic compounds PROCOMCURE BIOTECH GMBH (AT) 2019-06-11 — — US disclosed
US-20170368032-A1 Imidazole-Based Antimicrobial Agents PROCOMCURE BIOTECH GMBH (AT) 2017-12-28 — — US disclosed
US-20170340613-A1 Novel Imidazole-Based Heterocyclic Compounds PROCOMCURE BIOTECH GMBH (AT) 2017-11-30 — — US disclosed
US-20170334887-A1 Imidazole-Based Antimicrobial Agents PROCOMCURE BIOTECH GMBH (AT) 2017-11-23 — — US disclosed
EP-3226858-A1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS Procomcure Biotech GmbH (AT) 2017-10-11 — — EP disclosed
WO-2016087616-A1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS PROCOMCURE BIOTECH GMBH (AT) 2016-06-09 — — WO disclosed
WO-2016087618-A1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS PROCOMCURE BIOTECH GMBH (AT) 2016-06-09 — — WO disclosed
WO-2016087615-A1 NOVEL IMIDAZOLE-BASED HETEROCYCLIC COMPOUNDS PROCOMCURE BIOTECH GMBH (AT) 2016-06-09 — — WO disclosed
US-20130065897-A1 COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2013-03-14 — — US disclosed
EP-2515903-A1 COMPOUNDS, PREPARATIONS AND USES THEREOF Peter MacCallum Cancer Institute (AU) 2012-10-31 — — EP disclosed
WO-2011075784-A1 COMPOUNDS, PREPARATIONS AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2011-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334887-A1 Imidazole-Based Antimicrobial Agents TLR5, NISCH, SLC11A2 PRF1 1047/4885CYP2E1 2133/4885CYP3A4 2350/4885
US-10456379-B2 Imidazole-based antimicrobial agents TLR5, NISCH, SLC11A2 PRF1 1047/4885CYP2E1 2133/4885CYP3A4 2350/4885
US-10322110-B2 Imidazole-based antimicrobial agents ARG1, SLC11A2, IKZF3 PRF1 691/4885CYP2E1 387/4885CYP3A4 990/4885
US-20130065897-A1 COMPOUNDS, PREPARATION AND USES THEREOF PRF1, GZMB, SERPINB1 PRF1 1/4885CYP2E1 2226/4885CYP3A4 2225/4885
US-20170368032-A1 Imidazole-Based Antimicrobial Agents TLR5, NISCH, SLC11A2 PRF1 1047/4885CYP2E1 2133/4885CYP3A4 2350/4885
US-20170340613-A1 Novel Imidazole-Based Heterocyclic Compounds SLC11A2, MIF, NISCH PRF1 1977/4885CYP2E1 166/4885CYP3A4 339/4885
US-10314820-B2 Imidazole-based heterocyclic compounds MIF, SLC11A2, TLR5 PRF1 2244/4885CYP2E1 99/4885CYP3A4 209/4885
US-10875875-B2 Propionic acid derivatives and methods of use thereof ITGB3, ITGA1, ITGB5 PRF1 1453/4885CYP2E1 1826/4885CYP3A4 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.